JPRN-C000000282
Completed
Phase 1
Phase I/II Study of Combination Therapy of Oral Fluorinated Pyrimidine Compound S-1 with Low-dose Cisplatin in Patients with Unresectable and/or Recurrent Advanced Gastric Cancer Step 2: low dose cisplatin given twice a week + S-1
Japanese Foundation for Multidisciplinary Treatment of Cancer0 sites52 target enrollmentNovember 14, 2005
Conditionsunresectable or recurrent gastric cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- unresectable or recurrent gastric cancer
- Sponsor
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- Enrollment
- 52
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Histologically or cytologically demonstrated unresectable or recurrent gastric cancer
- •2\) With measurable or assessable legion(s)
- •3\) Without prior anti\-tumor therapy. Hormone therapy and/or immunotherapy within two weeks prior to enrollment are eligible. Postoperative adjuvant therapy not containing CDDP within one month prior to enrollment is eligible.
- •4\) Adequate bone marrow, hepatic and renal function
- •(1\)Hb \>\= 9\.0 g/dl
- •(2\)WBC 4,000 \- 12,000/mm3
- •(3\)neutrophils \>\= 2,000/mm3
- •(4\)platelets \>\= 100,000/ mm3
- •(5\)T\-Bil \<\= 1\.5mg/dl
- •(6\)GOT, GPT \<\= 2\.5 times of normal upper limits
Exclusion Criteria
- •1\) severe complication(s)
- •2\) symptomatic brain metastases
- •3\) active double cancers
- •4\) women who are currently pregnant, nursing, or plan to become pregnant
- •5\) cases where the investigator disapproved of participation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A feasibility study of combination with oral fluoropyrimidine, oxaliplatin and trastuzumab for HER2-positive advanced or recurrent gastric cancerHER2-positive unresectable advanced gastric cancerJPRN-UMIN000021554agoya University Hospital20
Completed
Not Applicable
Clinical evaluation of add-on administration of flavoxate hydrochloride in nocturia patients resistant to an anticholinergic agentJPRN-UMIN000009999Department of Urology, University of the Ryukyus50
Completed
Phase 1
Exploratory trial of a combination therapy of mFolfirinox and immunotherapy against pancreatic cancer.Pancreatic cancerJPRN-UMIN000026009Department of Gastroenterology and Hepatology, School of Medicine, Kochi University1
Active, not recruiting
Phase 1
Phase 1/2 Pharmacokinetic and Safety Study of Oral Phenoxodiol in Patients with Hormone-Refractory Prostatic AdenocarcinomaACTRN12605000512628Marshall Edwards Pty Ltd24
Recruiting
Phase 2
A phase II trial of combination therapy with palonosetron / dexamethasone or palonosetron / aprepitant / dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients with urothelial cancer.JPRN-UMIN000010460Yokohama city university80